BioSpace News Archive

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, announced the appointment of Evert Schimmelpennink to its Board of Directors.

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will release its fourth quarter and full year results after the market close on Tuesday, March 8, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced timing updates for two separate conference presentations.

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA).

Pulse Biosciences, Inc. today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer.

Engage Technologies Group, Inc. has selected Derek Johnson as Vice President of Engage Dental.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc.

908 Devices Inc. today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced a licensing and collaboration agreement.

Cytokinetics, Incorporated today announced topline results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv MecarbilRelated to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure